BOSTON - Entrada Therapeutics , Inc. (NASDAQ:TRDA) received authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial for its ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...

Analyst Gil Blum from Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

There is a simple discount patient access scheme for vamorolone. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Duchenne muscular dystrophy occurs when that gene fails ... These may include: Muscle biopsy. A small piece of muscle tissue is removed and examined to confirm the diagnosis or rule out another ...

Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical ...

Biomarkers of muscle magnetic resonance imaging (MRI) can be used as potential surrogate endpoints in clinical trials for patients with Duchenne muscular dystrophy (DMD), suggests a new study ...

In August 1985, I was diagnosed with Becker muscular dystrophy. So the doctors focused on the Becker type, as the majority of my presenting symptoms were similar to Duchenne’s ... defects in other ...

Also Read: Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy Dyne ... Analysis of muscle biopsy data for the 6.8 mg/kg Q8W cohort ...